Imel Biotherapeutics - Crunchbase Company Profile & Funding

Q: How much funding has Imel Biotherapeutics raised to date?

Imel Biotherapeutics has raised obfuscated.

Overview

Imel Biotherapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Imel Biotherapeutics

CB Rank

34619

Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders.

Founded

obfuscation

Private

Series A

Waltham, Massachusetts, United States

11-50

www.imelbiotx.com

Biotechnology

Life Science

Medical

Funding Rounds

Series A

OBF

obfuscation

Key People

Silvia Noiman: Founder & CEO

Details

Legal Name

Imel Biotherapeutics, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Silvia Noiman

About the Company

Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders. It uses a proprietary mitochondrial replaced cells technology, helping physicians to treat multiple patients with mitochondrial genetic or age-related disorders. The company was founded in 2019 and is based in Waltham, Massachusetts.

Diversity Spotlight

Women Founded

Women Led

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Autologous mitochondria-replaced T cells (Mir T Cells)

An intravenously infused cell therapy that reprograms aged immune cells by replacing dysfunctional mitochondria with healthy ones, restoring cellular functionality.

Mitochondrial Enhancement Therapy

A therapy that enhances mitochondrial function by replacing dysfunctional mitochondria with healthy ones to treat mitochondrial disorders.

Research & Development

Imel Biotherapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A
obfuscated obfuscation	Series A - Imel Biotherapeutics	—	obfuscated obfuscation	—	Series A